Browse 15 Tricuspid Regurgitation Medical Studies Across 90 Cities
240 Tricuspid Regurgitation Clinics
What Are Tricuspid Regurgitation Clinical Trials?
Tricuspid valve regurgitation is a valve disease. The tricuspid valve sits between the two chambers of the heart on the right. The valve consists of three thin tissue flaps. These flaps open to facilitate the flow of blood from the upper chamber to the lower chamber. These are tightly closed, preventing the blood from flowing backward. However, in tricuspid valve regurgitation, the valve on the two heart chambers on the right doesn’t close tightly, causing the blood to leak backward and enter the right atrium.
Most often, people have tricuspid regurgitation by birth. Hence, it is also considered a congenital heart disease. But other causes include genetic disorders, rheumatic fever, carcinoid syndrome, heart lining infection, and chest injury. Tricuspid regurgitation may also occur because of the removal or placement of a pacemaker that crosses the patient’s tricuspid valve.
Symptoms characterize the disease once it becomes severe. The symptoms may include irregular heartbeat, shortness of breath, belly swelling, neck veins and legs, and fatigue.
Tricuspid regurgitation clinical trials observe the development of disease in patients, their response to treatment, and the effects of medication on the progression of the disease.
Why Is Tricuspid Regurgitation Being Studied Through Clinical Trials?
Tricuspid valve regurgitation is the most common type of valvular cardiac disease. It is likely to affect 65 percent to 85 percent of the population. However, the severity of the condition is observed in approximately 1.6 million patients in the United States. The condition may become severe in patients with high blood pressure, pulmonary hypertension, cardiomyopathy, and those who seek medication for migraines. Moreover, tricuspid regurgitation results in complications like atrial fibrillation and heart failure. Hence tricuspid regurgitation clinical trials are underway to counter the issue.
Furthermore, trials are essential to finding the best and most effective preventative methods and cures for tricuspid valve regurgitation.
What Are the Types of Treatments Available for Tricuspid Regurgitation?
Depending on the tricuspid valve regurgitation severity, the doctor may advise you on medication or surgery. Medication helps address and manage uncomfortable symptoms like irregular heartbeat and swelling. It also prevents water retention while controlling the heart rate. However, surgery is needed to replace or repair the valve.
Tricuspid surgery uses general anesthesia to perform the surgery and keep the patient comfortable. The bypass machine is used for pumping blood during the procedure. Several tiny incisions are made in the chest, and one large incision is made on the right side of the chest. The damaged valve is repaired or replaced as needed. Next, the bypass machine is removed to ensure proper heart functioning, and incisions are closed.
What Are Some Recent Breakthrough Clinical Trials for Tricuspid Regurgitation?
2022: Tricuspid Valve Repair System Shows Promising Results at One-Year Follow-Up- In this feasibility study of the ITR (investigational transcatheter repair) system and one-year follow-up, results concluded with data from 36 patients. All patients experienced a reduction in one grade severity of tricuspid valve regurgitation, while 75 percent saw two grade reductions.
2022: Surgical management of tricuspid regurgitation- This observational and single-center study was performed on 76 patients with tricuspid regurgitation aimed to determine the algorithm efficacy of residual tricuspid regurgitation after tricuspid valve surgery. The study hypothesized that the tricuspid regurgitation rate after one year would be lowered by choosing the surgical approach in conformance with the preoperative echocardiographic and clinical variables. It was concluded that TR proved functional in 69.9 percent of the patients. More research needs to be conducted to confirm the findings.
Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Tricuspid Regurgitation Clinical Trial Research?
The team at HVC has over 40 years of heart valve replacement and repair experience. From intensive research to medical care, they are innovators and experts caring for people with tricuspid and aortic diseases.
It targets the unmet medical and clinical needs of patients with heart valve diseases. The program conducts research to find effective treatments.